Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids

Fig. 4

a: Baseline CEA expression profile measured by FACS, gates for sorting of CEAlo and CEAhi cells and CEA expression profiles of the sorted cells following re-expansion for 1 month. Sorting dot-blots also show GFP positivity of the PDO lines including a subpopulation of genome doubled cancer cells, that shows increased GFP signal due to higher histone content, which was repeatedly observed in CRC-08. b: Growth curves of sorted CEAhi and CEAlo PDO cells that had been re-expanded for 1 month before cibisatamab sensitivity was re-analysed in the PDO and T cell co-culture assay at an E:T ratio of 2:1

Back to article page